Objective: To determine the molecular mechanism of ligand-dependent transrepression in vascular smooth muscle cells and their impact on the vascular protective actions of PPAR␥.
T he peroxisome proliferator-activated receptor ␥ (PPAR␥) belongs to the nuclear receptor family of ligand-dependent transcription factors. 1 PPAR␥ plays an important role in glucose homeostasis and is pharmacologically targeted by the class of insulin-sensitizing drugs named thiazolidinediones or glitazones. 1, 2 In addition to its critical metabolic function, glitazone-activated PPAR␥ exhibits potent anti-inflammatory and vascular protective effects by directly affecting gene expression in monocytes/macro-phages, T lymphocytes, endothelial cells, and vascular smooth muscle cells (VSMCs). 3, 4 PPAR␥-mediated gene regulation comprises several distinct mechanisms, including ligand-dependent transactivation, ligand-independent repression, and ligand-dependent transrepression. 4 For its anti-inflammatory actions in macrophages, inhibition of gene expression by ligand-dependent transrepression has been identified as a key molecular process. 5 However, the molecular mechanisms underlying PPAR␥-mediated transcriptional repression in vascular cells are largely unknown.
Matrix metalloproteinase-9 (MMP-9) and endothelin-1 (ET-1) are PPAR␥ target genes in vascular cells involved in the development of atherosclerosis and have been characterized as important mediators of the vascular protective actions of PPAR␥. 6 -8 PPAR␥ activation by glitazones results in marked inhibition of MMP-9 mRNA/protein expression and its gelatinolytic activity in VSMCs, which indicates MMP-9 as a potential candidate gene for ligand-dependent transrepression in these cells. 8 High-mobility group (HMG) proteins are chromatinbinding proteins that consist of the 3 family members HMGA, HMGB, and HMGN. 9 HMG proteins act as architectural elements that affect various DNA-dependent processes in the context of chromatin. 9 Via DNA-protein or protein-protein interactions, HMG proteins regulate gene transcription and influence multiple biological processes, including cell growth, proliferation, differentiation, and death. 9 The present study aimed to characterize the molecular process of ligand-dependent transrepression by PPAR␥activating ligands in vascular cells. We focused on the MMP-9 gene as a model for negatively regulated genes by PPAR␥ in VSMCs. To identify new coregulators of PPAR␥, we performed expression profiling analyses of nuclear coregulators (SuperArray) in VSMCs. The chromatinmodifying transcriptional coregulator HMGA1 was identified and characterized as a new regulator of PPAR␥-mediated transrepression in VSMCs. The relevance of these processes was tested in HMGA1 Ϫ/Ϫ mice undergoing wire-induced mechanical injury of the femoral artery in the presence of glitazone-mediated PPAR␥ activation.
Methods

Animals
All animal procedures and care were performed and provided at the animal facility at the Instituto de Napoli, Universita di Napoli Federico II using approved protocols in accordance with institutional guidelines. HMGA1 Ϫ/Ϫ mice and wild-type controls (both on a C57BL6/ 129SBJ background) were housed at room temperature with a 12-hour light/dark cycle with food and water provided ad libitum. Generation of HMGA1 Ϫ/Ϫ mice has been described previously. 10 Male mice (nϭ5 per group) were randomly assigned to vehicle or pioglitazone treatment beginning 5 days before intervention and continuing for 3 weeks after injury. Pioglitazone (10 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ) and vehicle (0.9% NaCl) were given once daily by oral gavage. Serum glucose was assessed with a glucometer (Precision Xtra; Abbott Laboratories, Abbott Park, IL), and serum insulin was determined by ELISA according to the manufacturer's instructions (Linco Research Immunoassay, St Charles, MO).
Mouse Femoral Artery Injury Model of Neointima Formation
HMGA1 Ϫ/Ϫ mice and wild-type controls underwent mechanical injury of the femoral artery by insertion of a straight spring wire, as described previously. 11 Twenty-one days after injury, mice were perfused via the left ventricle with 0.9% NaCl solution, and the femoral artery was excised and embedded in Tissue-Tek freezing medium (Jung Leica, Deerfield, IL), snap-frozen, and stored at Ϫ80°C. 12, 13 All other detailed protocols are provided in the online-only Data Supplement (available at http://circres.ahajournals.org).
Results
HMGA1 Deletion Prevents MMP-9 and ET-1 Repression by Ligand-Activated PPAR␥
To discover new coregulators of PPAR␥ in VSMCs, expression profiling of nuclear coregulators in human aortic VSMCs was performed with an Oligo GEArray Human Nuclear Receptors & Coregulators Microarray (SA Biosciences, a Qiagen company; Valencia, CA; Figure 1A ). We identified HMGA1 as the nuclear coregulator with the highest expression level in human aortic VSMCs. HMGA1 protein expression in VSMCs was confirmed by Western blotting ( Figure 1B) .
We next investigated the role of HMGA1 for PPAR␥mediated MMP-9 and ET-1 repression by loss-of-function experiments using specific small interfering RNA (siRNA) in VSMCs. Transfection of HMGA1 siRNA effectively abolished HMGA1 mRNA and protein expression ( Figure 1B ). The absence of HMGA1 in VSMCs completely prevented MMP-9 and ET-1 inhibition by glitazone-activated PPAR␥ (Figures 1B and C). HMGA1 silencing had no effect on phorbol-12-myristate-13-acetate (PMA)-induced MMP-9/ ET-1 regulation in the absence of PPAR␥ activation (Figures 1B and C) . Furthermore, knockdown of HMGA1 also prevented PPAR␥-mediated inhibition of MMP-9 expression induced by the proinflammatory stimulator tumor necrosis factor-␣ ( Figure 1D ).
Gain-of-function studies with overexpression of human HMGA1 in VSMCs resulted in strongly amplified pioglitazone-induced MMP-9 repression, which corroborates the role of HMGA1 ( Figure 1E ). To confirm the importance of PPAR␥ in this pathway and to exclude PPAR␥independent actions of glitazones, we next examined MMP-9 regulation in VSMCs after PPAR␥ knockdown by siRNA. Reduction of PPAR␥ in VSMCs completely abolished the inhibitory effects of pioglitazone on MMP-9 expression, which showed that the actions of pioglitazone were PPAR␥ dependent ( Figure 1F ).
To further determine the specificity of the action of HMGA1 on PPAR␥, additional nuclear receptors involved in VSMC function were investigated. Ligands for the liver X receptor have been shown to inhibit VSMC proliferation via suppression of 2 cell cycle-regulating proteins, S-phase kinase-associated protein 2 (Skp2), and minichromosomal maintenance protein 6 (MCM6). 14 show mRNA and protein levels of HMGA1 after siRNA knockdown in VSMCs 24 hours after transfection. VSMCs were starved for 36 hours, followed by transfection with siRNA as indicated, and 24 hours later were stimulated with PMA (50 ng/mL) with or without pioglitazone (Pio; 10 mol/L) for 10 hours. MMP-9 (B, right) and ET-1 (C) expression was analyzed by quantitative real-time PCR. *PϽ0.01 vs vehicle; #PϽ0.01 vs PMA. Results represent data from 3 independent experiments performed in triplicate. D, VSMCs were starved for 36 hours, followed by transfection with HMGA1 siRNA as indicated, and 24 hours later were stimulated with tumor necrosis factor-␣ (TNF␣; 100 ng/mL) with or without Pio (10 mol/L) for 24 hours, and MMP-9 expression was analyzed by quantitative real-time PCR. *PϽ0.01 vs vehicle;#PϽ0.01 vs PMA. Figure 1G , knockdown of HMGA1 did not affect the inhibition of mitogen-induced Skp2 or MCM6 expression by the liver X receptor ligand T1317. In addition, HMGA1 depletion had no effect on liver X receptor-mediated suppression of mitogen-induced VSMC proliferation, whereas the inhibitory effects of pioglitazone on VSMC proliferation were abolished in the absence of HMGA1 ( Figure 1H ). Specificity of action of HMGA1 on the PPAR␥ pathway ultimately was supported by the absence of any HMGA1-mediated effect on rapamycin-induced inhibition of VSMC growth ( Figure 1H ). These results demonstrate that HMGA1 is a molecular mediator of PPAR␥-mediated MMP-9 and ET-1 gene transcription in VSMCs, thereby affecting PPAR␥ actions on VSMC function.
HMGA1/PPAR␥-Dependent MMP-9 Promoter Regulation Interferes With Nuclear Factor-B Regulatory Elements
To further characterize the molecular mechanism of the HMGA1-PPAR␥ axis in VSMCs, we subsequently focused on the transcriptional regulation of the MMP-9 gene. HEK293 cells overexpressing PPAR␥/retinoid X receptor-␣ were transfected with the human MMP-9 fulllength promoter fused to a luciferase reporter gene (pGL3-MMP-9/Ϫ2176/ϩ54). In accordance with the mRNA expression data, PPAR␥ activation by pioglitazone significantly inhibited PMA-induced MMP-9 promoter activity ( Ϫ604). 15 To analyze the relevance of these sites for MMP-9 repression by PPAR␥, different deletion constructs were generated. Promoter activity was unchanged by deletion of the Ϫ2176 to Ϫ670 region ( Figure 2A ). Deletion of the proximal promoter region (construct Ϫ670 to Ϫ512), which eliminates the proximal AP-1 binding site, did not affect regulation by PMA or pioglitazone ( Figure 2A) ; however, deletion of the Ϫ670 to Ϫ603 region, which only disrupts the NF-B element at Ϫ604
while keeping the other sites intact, strongly reduced MMP-9 promoter activation by PMA, as well as PPAR␥mediated inhibition (Figure 2A ). In consonance, a singlenucleotide mutation within the NF-B element diminished the action of PMA and pioglitazone on MMP-9 promoter activity ( Figure 2B ). Together, these data show that among the known cis-acting regulatory elements of the MMP-9 promoter, NF-B might be involved in PPAR␥-mediated actions.
Repression of MMP-9 promoter activity by glitazoneinduced PPAR␥ was undetectable in cells transfected with HMGA1 siRNA, which suggests that HMGA1 is required for the inhibitory action of PPAR␥ on the MMP-9 promoter ( Figure 2C ). In contrast, HMGA1 was not required for ligand-dependent PPAR␥-mediated activation of a peroxisome proliferator response element-driven luciferase reporter (Online Figure I, B ). To determine whether other NF-B-regulated genes in VSMCs are under the control of PPAR␥ and HMGA1, we analyzed additional genes with known putative NF-B binding sites in their promoters. As shown in Online Figure IC, PMAmediated induction of the majority of the genes was suppressed by pioglitazone. However, in only a subset of genes, absence of HMGA1 prevented PPAR␥-mediated inhibition, which implies that additional factors may determine the impact of HMGA1-PPAR␥ interactions on NF-B-regulated genes.
PPAR␥/HMGA1-Mediated Transrepression of MMP-9 Involves PPAR␥ SUMOylation and SMRT Binding
Previously, Pascual and colleagues 5 identified a new molecular pathway by which PPAR␥ represses gene activation in macrophages that involves Ubc9 (ubiquitin-like protein SUMO-1 conjugating enzyme)-dependent PPAR␥ SUMOylation and prevention of corepressor removal from gene promoters. Ubc9, the rate-limiting SUMO E2 ligase, has been identified recently as an HMGA1 interacting protein. 16 Thus, we hypothesized that this molecular pathway might also be involved in PPAR␥/HMGA1-mediated regulation of the MMP-9 promoter. show mRNA and protein levels of PPAR␥ after siRNA knockdown in VSMCs 24 hours after transfection. VSMCs were starved for 36 hours, followed by transfection with siRNA as indicated, and 24 hours later were stimulated with PMA (50 ng/mL) with or without Pio (10 mol/L; right) for 10 hours. MMP-9 expression was analyzed by quantitative real-time PCR. *PϽ0.01 vs vehicle; #PϽ0.01 vs PMA. Results represent data from 3 independent experiments performed in triplicate. G, VSMCs were starved for 36 hours, followed by transfection with siRNA as indicated, and 24 hours later were stimulated with platelet-derived growth factor (PDGF; 20 ng/mL) and insulin (1mol/L) with or without T1317 (5 mol/L) for 24 hours, and S-phase kinase-associated protein 2 (Skp2) and minichromosomal maintenance protein 6 (MCM6) expression was analyzed by quantitative real-time PCR. *PϽ0.01 vs vehicle; #PϽ0.01 vs PDGF/insulin. Results represent data from 3 independent experiments performed in triplicate. H, VSMCs were seeded onto 96-well plates; after 24 hours' transfection with control and HMGA1 siRNA, cells were incubated for an additional 24 hours in the presence or absence of 10% FCS. After 48 hours' treatment with Pio (10 mol/L), the liver X receptor-␣ agonist (T1317; 5 mol/L), or rapamycin (Rapa; 10 nmol/L), cells were harvested and cell proliferation was determined by MTS proliferation assay. SUMOylation of PPAR␥ was tested in pioglitazonetreated cells that overexpressed SUMO1 and PPAR␥ in the absence and presence of HMGA1 overexpression. As shown in Figure 2D , pioglitazone-induced SUMOylation of PPAR␥ was markedly enhanced in the presence of HMGA1. SUMOylation of the PPAR␥ ligand-binding domain at residue K367 is required for ligand-dependent transrepression of the inducible nitric oxide synthase promoter, whereas SUMOylation of K97 within the AF-1 domain of PPAR␥ is involved in ligand-dependent gene activation. 5, 17 To study the role of PPAR␥ SUMOylation for PPAR␥/HMGA1-mediated transrepression of the MMP-9 promoter, PPAR␥ SUMOylation sites were mutated, and MMP-9 promoter regulation was investigated. Mutation of K97 to arginine (K97R) did not affect PPAR␥mediated inhibition of MMP-9 promoter activity or HMGA1-dependent regulation of this process ( Figure 2E ). In contrast, when K367 within the PPAR␥ ligand-binding domain was mutated to K367R, PPAR␥-mediated transrepression was abolished, and the action of HMGA1 on this process was completely abrogated ( Figure 2E ). To further support the involvement of SUMOylation, we studied the interaction between HMGA1 and the SUMO E2 ligase Ubc9 by immunoprecipitation experiments. Under the basal condition, only very weak binding between HMGA1 and Ubc9 was detectable ( Figure 2F) ; however, in the presence of the PPAR␥ ligand pioglitazone, HMGA1-Ubc9 interaction was enhanced ( Figure 2F ). Furthermore, in addition to ligand-induced Ubc9-HMGA1 interaction, pioglitazone/PMA treatment resulted in HMGA1-PPAR␥ binding ( Figure 2G ). No interaction was detected between PPAR␥ and the p65 subunit of NF-B ( Figure 2H ). Together, these data demonstrate that ligand-dependent PPAR␥-mediated transrepression of MMP-9 and its regulation by HMGA1 requires SUMOylation at K367, a process that depends on the E2 ligase Ubc9. 5 After ligand stimulation, PPAR␥ forms a complex with HMGA1-Ubc9, which likely facilitates its SUMOylation.
To examine the role of HMGA1 in ligand-dependent recruitment of PPAR␥ to the MMP-9 promoter, chromatin immunoprecipitation (ChIP) assays were performed. Induction of MMP-9 transcription by PMA was associated with the recruitment of RNA polymerase II, a fundamental component of the basal transcription apparatus, p65 recruitment, and the parallel attenuated binding of the nuclear corepressor SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) from the MMP-9 promoter ( Figure 3A) . Interestingly, PMA stimulation also resulted in moderate recruitment of PPAR␥ to the promoter ( Figure 3A) . In cells treated with pioglitazone, PPAR␥ was markedly recruited to the MMP-9 promoter, accompanied by enhanced binding of HMGA1 ( Figure  3A) . Concurrent with the recruitment of the PPAR␥-HMGA1 complex under pioglitazone treatment, reduction of SMRT corepressor binding was prevented, and p65 binding was reduced but not completely abolished ( Figure  3A) . In parallel, ligand-dependent interaction between PPAR␥-SMRT could be detected in immunoprecipitation experiments, which underscores the relevance of SMRT-PPAR␥ interactions for this process (Online Figure I, D) .
To further study the relevance of HMGA1 for these processes, we used siRNA directed against HMGA1 in ChIP assays. Absence of HMGA1 resulted in a complete loss of PPAR␥ binding to the MMP-9 promoter ( Figure  3B ). This was associated with abrogated binding of SMRT and enhanced binding of p65 ( Figure 3B ). Two additional NF-B-regulated promoters inhibited by pioglitazone (platelet-derived growth factor and vascular cell adhesion protein) were studied for PPAR␥, p65, and cofactor binding by ChIP analysis (Online Figure II, A through D) . In consonance with the mRNA expression data, binding of PPAR␥, HMGA1, and SMRT to the platelet-derived growth factor promoter followed a similar pattern observed for the MMP-9 promoter, with the exception of p65 reduction after pioglitazone treatment (Online Figure II, A  and B ). In accordance with the lack of vascular cell adhesion protein mRNA regulation by HMGA1, ChIP analysis revealed almost no binding of PPAR␥, HMGA1, and SMRT after pioglitazone stimulation (Online Figure II , C and D).
Because PPAR␥-dependent prevention of corepressor clearance recently has been shown to depend on PPAR␥ SUMOylation, 5 the present data suggest that the liganddependent formation of HMGA1-Ubc9-PPAR␥ complexes facilitates ligand-dependent PPAR␥ SUMOylation, which results in maintenance of the SMRT corepressor on the MMP-9 promoter and transrepression. This process occurs in a promoter-specific manner.
Ligand-Mediated Vascular Protection by PPAR␥ Is Abolished in HMGA1 ؊/؊ Mice
In the mouse vascular injury model, MMP-9 substantially drives vascular pathology such as neointima formation, a process potently blocked by glitazone-activated PPAR␥. 6, 18 To prove the relevance of the PPAR␥-HMGA1 pathway for PPAR␥-dependent vascular protection, we examined neointima formation after mechanical injury of the femoral artery in HMGA1 Ϫ/Ϫ mice treated with the PPAR␥-ligand pioglitazone. In this model, the neointima is exclusively composed of VSMCs, whereby only a few macrophages occur in the adventitia. 19 Arterial injury resulted in the prominent formation of a neointima in wild-type and HMGA1 Ϫ/Ϫ mice ( Figure 4A ). Treatment of mice with pioglitazone significantly reduced neointima formation in wild-type mice by 50% as evaluated by quantitative morphometry (Figures 4A and 4B ). In contrast, this effect was completely abolished in HMGA1 Ϫ/Ϫ mice (Figures 4A and 4B) .
As described previously, 20,21 after vascular injury, MMP-9 staining was detected both in the medial and the neointimal layer, with a stronger expression in the vessel media ( Figure  4C ). Injury-mediated vascular MMP-9 upregulation was reduced by pioglitazone in wild-type mice but not in HMGA1 Ϫ/Ϫ mice (Figures 4C and 4D) .
In consonance with our in vitro data, repression of vascular ET-1 by pioglitazone was also abolished in HMGA1 Ϫ/Ϫ mice ( Figure 4D ). During neointima formation, VSMCs undergo phenotypic changes and switch from a contractile phenotype to a synthetic phenotype. 22 We tested different smooth muscle cell markers for contractile and synthetic modulation in femoral arteries from uninjured or injured wild-type and HMGA1 Ϫ/Ϫ mice. As shown in Figure 4D , ␣-smooth muscle actin, a marker for the contractile phenotype, declined significantly after injury in wild-type and HMGA1 Ϫ/Ϫ mice. Pioglitazone partially prevented the fall in ␣-smooth muscle actin only in wild-type mice. Correspondingly, the marker for the synthetic VSMC phenotype SMemb (nonmuscle myosin heavy chain B) increased markedly after injury in both genotypes, and the action of pioglitazone on this modulation was attenuated in HMGA1 Ϫ/Ϫ mice ( Figure 4D ). The marker SM1 was regulated neither by injury nor by genotype or treatment ( Figure 4D ). Together, these data show that pioglitazone prevents an injury-induced phenotypic VSMC switch, an effect attenuated in HMGA1 Ϫ/Ϫ mice.
To evaluate whether the vascular actions of pioglitazone are associated with effects on systemic insulin and glucose metabolism, serum insulin and glucose levels were analyzed. As described previously, 10 glucose levels did not differ between genotypes, and pioglitazone treatment had no significant effect (serum glucose, in mmol/L: vehicletreated-wild-type 6.4Ϯ0.6, HMGA1 Ϫ/Ϫ 6.7Ϯ1.0; pioglitazone-treated-wild-type 6.8Ϯ1.3, HMGA1 Ϫ/Ϫ 7.9Ϯ1.0). Serum insulin levels were significantly lower in HMGA1 Ϫ/Ϫ vehicle-treated mice (0.7Ϯ0.2 ng/mL) than in wild-type mice (1.3Ϯ0.1 ng/mL, PϽ0.05). Pioglitazone treatment had no significant effect on serum insulin compared with vehicle controls, independent of the genotype (pioglitazone-treated mice: wild-type 1.5Ϯ0.6 ng/mL, PϭNS versus vehicle; HMGA1 Ϫ/Ϫ 1.2Ϯ0.3 ng/mL, PϭNS versus vehicle).
Finally, we demonstrated that HMGA1 deficiency did not interfere with pioglitazone-mediated transcriptional activation of CD36 and adiponectin in gonadal adipose tissue (Online Figure I, E) . These data provide evidence for the absence of HMGA1 action on PPAR␥-dependent transactivation and underline its predominant role for transrepression.
Together, these results suggest that HMGA1 is required for the vascular protective actions of PPAR␥-activating glitazones that involve vascular MMP-9 and ET-1 regulation.
Discussion
The present study characterizes a molecular pathway in VSMCs by which ligand-activated PPAR␥ represses transcriptional activation of the MMP-9 gene, a gene crucial for the antiatherosclerotic actions of PPAR␥. Ligand-mediated transrepression in VSMCs requires PPAR␥ SUMOylation, which has been shown to be mediated by the rate-limiting SUMO E2 ligase Ubc9. HMGA1 is a Ubc9 and PPAR␥ interacting protein, involved in PPAR␥ SUMOylation, and its deficiency disrupted PPAR␥mediated transrepression of the MMP-9 gene. In addition, the absence of HMGA1 prevented the binding of PPAR␥ to the MMP-9 promoter associated with reduced SMRT corepressor binding. These data suggest that HMGA1 is involved in vascular PPAR␥-mediated transrepression by facilitating PPAR␥ SUMOylation through Ubc9, a process that maintains corepressor binding to the MMP-9 promoter. The critical importance of this pathway is underlined by the loss of glitazone-mediated vascular protection through PPAR␥ activation in HMGA1-deficient mice undergoing arterial injury.
Ligand-dependent transrepression has been characterized as a crucial mechanism for the inhibition of inflammatory gene expression by PPAR␥. 5 Here, we have identified the HMGA1 protein as a coregulator of PPAR␥ transrepression in VSMCs. One mechanism of ligandmediated transrepression in VSMCs has been described recently for PPAR␣ and inhibition of AP-1/NF-B-dependent interleukin-6 promoter activation. 23 In this study, transcriptional interference occurred independent of the promoter context and involved a physical interaction between PPAR␣ and c-Jun/p65 complexes. 23 Previously, Pascual and colleagues 5 identified a new molecular pathway by which PPAR␥ represses gene activation in macrophages that involved Ubc9-dependent PPAR␥ SUMOylation and prevention of corepressor removal from the inducible nitric oxide synthase promoter. Ubc9 is the rate-limiting SUMO E2 ligase and recently has been identified as an HMGA1 interacting protein. 16 Thus, we hypothesized that HMGA1 might be involved in PPAR␥ SUMOylation by interacting with Ubc9. In accordance with this hypothesis, we could show that PPAR␥-mediated transrepression of the MMP-9 gene, and its regulation by HMGA1 depended on SUMOylation of the PPAR␥ ligandbinding domain at K367, the same site identified by Pascual and colleagues. 5 Furthermore, we demonstrated that HMGA1 interacts with Ubc9 and PPAR␥, which provides the prerequisite for PPAR␥ SUMOylation by Ubc9. PPAR␥-mediated transrepression involves the prevention of nuclear corepressor clearance from target promoters, a process that requires PPAR␥ SUMOylation. 5 The absence of HMGA1 inhibited PPAR␥ binding to the MMP-9 promoter and allowed PMA-induced reduction of SMRT-corepressor binding, which suggests that HMGA1 is required for SMRT maintenance on the MMP-9 promoter, which may involve its action on PPAR␥ SUMOylation.
SMRT-containing complexes are now recognized to substantially repress NF-B transactivation, a process essential for PMA-mediated MMP-9 induction. 15, 24, 25 Here, we have shown that PPAR␥ physically interacts with SMRT in a ligand-dependent manner. Previously, Nofsinger and colleagues 26 demonstrated that the corepressor SMRT binds to PPAR␥ via its 2 receptor-interacting domains. Furthermore, SMRT recently has been shown to be involved in nuclear receptor-mediated transrepression, which also suggests a crucial role for this corepressor in PPAR␥-mediated transrepression in our model. 27 Involvement of NF-B repression by PPAR␥-HMGA1-SMRT complexes is further supported by the lack of any inhibitory ligand-induced PPAR␥ effects when parts of the NF-B site are deleted or mutated by a site-directed 2-bp mutation within the NF-B element in the MMP-9 promoter. In addition, we showed that the HMGA1-PPAR␥ complex also repressed tumor necrosis factor-␣-induced MMP-9 regulation. Tumor necrosis factor-␣ previously 28 has been shown to induce MMP-9 promoter activity, at least in part, via the NF-B site described in the present study. To determine whether other NF-B-regulated genes are modulated by the same mechanism, we analyzed the expression of additional genes containing putative NF-B binding sites in their promoters and the binding of PPAR␥, HMGA1, p65, and SMRT. In this analysis, involvement of HMGA1 in PPAR␥-mediated transrepression could only be detected in a subset of genes, which implies that additional factors may determine the impact of HMGA1-PPAR␥ interactions on NF-B-regulated genes. The following mechanisms may be involved: Previously, Leung and colleagues 29 described that a single nucleotide difference within NF-B sites of different target promoters changed the regulatory activity of the transcription factor. These data suggest a high level of promoter-specific regulation among NF-B target promoters, a process that might also be relevant for its transrepression. In addition, PPAR␥-mediated inhibition of NF-B-regulated promoters may also occur in the absence of PPAR␥-HMGA1 promoter interaction (eg, vascular cell adhesion protein promoter), involving indirect mechanisms such as phosphorylation of crucial transcriptional coregulators such as histone deacetylases. 30 Furthermore, NF-B p65 binding to the MMP-9 promoter was attenuated, but not completely abolished, by PPAR␥ ligand stimulation. This process was blocked in the absence of HMGA1. Recently, Hamblin and colleagues 31 showed that p65 nuclear translocation is attenuated by PPAR␥ via regulation of IB phosphorylation. Interestingly, PPAR␥ can physically interact with p65 in a ligand-dependent manner, a process we could not confirm in our model. 32 Together, these data suggest that in addition to the role of HMGA1 in PPAR␥ SUMOylation, the protein might also be involved in PPAR␥mediated inhibition of p65 translocation involving PPAR␥-dependent regulation of the phosphorylation status of an upstream mediator such as IB. To further determine whether HMGA1 affects the PPAR␥-p65 axis, p65 trans-location, and/or IB phosphorylation, additional experiments would be required. Finally, PPAR␥ liganddependent inhibition of NF-B-regulated genes may also occur in an HMGA1-independent manner.
To prove the relevance of PPAR␥-HMGA1-dependent MMP-9 repression for the protective vascular actions of PPAR␥, HMGA1 Ϫ/Ϫ mice undergoing mechanical arterial injury were treated with the PPAR␥ ligand pioglitazone. Pioglitazone significantly reduced neointima formation after arterial injury in wild-type mice. These data are consistent with previously published reports demonstrating a protective action of various PPAR␥ ligands in rodent models of vascular injury. 18, 33 MMP-9 is a central mediator of the new-forming neointima in injured vessels, and its inhibition has been reported to be a crucial component of the inhibitory effects of PPAR␥ on postinjury neointima formation. 6,8 MMP-9 not only affects VSMC migration from the media to the neointima but also regulates VSMC proliferation in injured arteries. 6 According to the lack of PPAR␥-mediated repression of MMP-9 and VSMC proliferation in vitro in the absence of HMGA1, the blockade of neointima formation by pioglitazone was completely abolished in HMGA1 Ϫ/Ϫ mice. These data support the importance of the PPAR␥-HMGA1 pathway for the vascular protective actions of PPAR␥. Furthermore, the lack of therapeutic effect was accompanied by the absence of pioglitazone-induced MMP-9 reduction in injured arteries of HMGA1 Ϫ/Ϫ mice.
However, additional factors may have influenced our results. For instance, the lack of additional beneficial metabolic effects by pioglitazone in HMGA1 Ϫ/Ϫ mice could have affected the present in vivo studies. As reported recently, HMGA1 Ϫ/Ϫ mice show decreased insulin receptor expression, which results in impaired insulin responses, in particular in the liver, and severely impaired insulin secretion that causes impaired glucose tolerance. 10 An important feature of the metabolic phenotype of HMGA1 Ϫ/Ϫ mice includes low plasma insulin levels and tissue-specific insulin resistance, with increased muscle/fat and isolated decreased liver insulin sensitivity. 10 Thus, regular vascular insulin sensitivity is likely in HMGA1 Ϫ/Ϫ mice. In consonance, neointima formation was similar in untreated wild-type and HMGA1 Ϫ/Ϫ mice compared with uninjured mice, which supports a minor role of the metabolic phenotype on the vascular injury response in our model. In addition, we could not detect any effect of pioglitazone on serum insulin or glucose levels. These data make it unlikely that the absence of pioglitazone-induced effects on neointima formation in HMGA1 Ϫ/Ϫ mice is mediated via metabolic actions.
Together, in the present study, we identified a new molecular pathway for PPAR␥-dependent transrepression based on the interaction with HMGA1 in VSMCs. This pathway appears to play a crucial role in the glitazonemediated protective vascular actions of PPAR␥. Characterization of PPAR␥-dependent tissue-or cell-specific transcriptional networks provides the foundation for the development of new selective PPAR␥ modulators (SPPARMs). 34 On the basis of this information, new selective PPAR␥ modulators with a specific cofactor binding profile could be designed to improve a specific clinical efficacy and to reduce side effects. HMGA1 represents 1 crucial cofactor that should be recruited to ameliorate PPAR␥-mediated vascular protection.
